Abstract
Due to the wide range of chemical structures and variety of mechanisms of action of antischizophrenic agents, it is difficult to identify and confirm a common pharmacophore. The present review summarizes various pharmacophore models for antischizophrenic activity including those based on the new targets, the kynurenine aminotransferase (KATs), which may facilitate the development of novel drugs. Some models illustrate the structural differences of compounds with mechanisms of action considered similar, and yet others demonstrate pharmacophore models for similar chemical classes of compounds for which the mechanism of antischizophrenic action is still not clear. In this study, we discuss the pharmacophore models for antipsychotics including phenothiazine, butyrophenone, thioxanthene, and atypical agents along with the novel antischizophrenic agents which are inhibitors of KATs isozymes.
Keywords: Antipsychotic, antischizophrenic, dopamine D2, pharmacophore, KATs inhibitors, serotonin 5-HT2A.
Graphical Abstract
Medicinal Chemistry
Title:Essential Structural Features of Novel Antischizophrenic Drugs: A Review
Volume: 10 Issue: 6
Author(s): Alireza Nematollahi, Noushin Aminimoghadamfarouj and William Bret Church
Affiliation:
Keywords: Antipsychotic, antischizophrenic, dopamine D2, pharmacophore, KATs inhibitors, serotonin 5-HT2A.
Abstract: Due to the wide range of chemical structures and variety of mechanisms of action of antischizophrenic agents, it is difficult to identify and confirm a common pharmacophore. The present review summarizes various pharmacophore models for antischizophrenic activity including those based on the new targets, the kynurenine aminotransferase (KATs), which may facilitate the development of novel drugs. Some models illustrate the structural differences of compounds with mechanisms of action considered similar, and yet others demonstrate pharmacophore models for similar chemical classes of compounds for which the mechanism of antischizophrenic action is still not clear. In this study, we discuss the pharmacophore models for antipsychotics including phenothiazine, butyrophenone, thioxanthene, and atypical agents along with the novel antischizophrenic agents which are inhibitors of KATs isozymes.
Export Options
About this article
Cite this article as:
Nematollahi Alireza, Aminimoghadamfarouj Noushin and Church Bret William, Essential Structural Features of Novel Antischizophrenic Drugs: A Review, Medicinal Chemistry 2014; 10 (6) . https://dx.doi.org/10.2174/1573406410666131229150746
DOI https://dx.doi.org/10.2174/1573406410666131229150746 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Therapy for the Prevention of Ischemia / Reperfusion Injury in Organ Transplantation
Current Gene Therapy Validated Microemulsion Liquid Chromatography-Fluorescence Method for the Quantification of Duloxetine and its Two Main Metabolites in Plasma: Application to Clinical Pharmacokinetic Studies
Current Pharmaceutical Analysis Inflammation, Serotonin and Major Depression
Current Drug Targets Recents Patents for Isolating, Delivering and Tracking Adult Stem Cells in Regenerative Medicine
Recent Patents on Drug Delivery & Formulation Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3
Central Nervous System Agents in Medicinal Chemistry Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Risks Associated with Vortioxetine in the Established Therapeutic Indication
Current Neuropharmacology Evaluating a Child with Partial Developmental Delay (ParDD), Global Developmental Delay (GDD)/Mental Retardation (MR): Clinical Expertise Based or Evidence-Based?
Current Pediatric Reviews γ-Secretase as a Therapeutic Target for Treatment of Alzheimers Disease
Current Pharmaceutical Design Epigenetic Studies in Psychotherapy: A Systematic Review
Current Psychiatry Research and Reviews Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls
Current Drug Targets Development of Effective PET and SPECT Imaging Agents for the Serotonin Transporter: Has a Twenty-Year Journey Reached its Destination?
Current Topics in Medicinal Chemistry Alzheimer's Disease: Emerging Trends in Small Molecule Therapies
Current Medicinal Chemistry Nose to Brain Drug Delivery System: A Comprehensive Review
Drug Delivery Letters Neurodegeneration and Neuroprotective Agents in Multiple Sclerosis
Recent Patents on CNS Drug Discovery (Discontinued) Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Editorial (Hot Topic: Epidemiology & Risk Factors for Alzheimer’s Disease)
Current Alzheimer Research Role of the α7 Nicotinic Acetylcholine Receptor and RIC-3 in the Cholinergic Anti-inflammatory Pathway
Central Nervous System Agents in Medicinal Chemistry Caveolin-1 in Stroke Neuropathology and Neuroprotection: A Novel Molecular Therapeutic Target for Ischemic-Related Injury
Current Vascular Pharmacology Medications Acting on the Dopaminergic System in the Treatment of Alcoholic Patients
Current Pharmaceutical Design